Drug Patents owned by Actelion

1. List of Opsumit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10946015 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Sep, 2026

(3 years from now)

US9265762 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
May, 2027

(4 years from now)

US8367685 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Oct, 2028

(5 years from now)

US8268847 ACTELION Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Apr, 2029

(6 years from now)

Drugs and Companies using MACITENTAN ingredient

Market Authorisation Date: 18 October, 2013

Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition; Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition; Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties

Dosage: TABLET;ORAL

How can I launch a generic of OPSUMIT before it's patent expiration?
More Information on Dosage

OPSUMIT family patents

18

United States

8

European Union

4

Japan

4

IB

4

Norway

3

Korea, Republic of

3

Brazil

3

Australia

3

Malaysia

3

Spain

3

Israel

3

South Africa

3

Portugal

3

China

3

Canada

3

New Zealand

3

Denmark

2

Hong Kong

2

Poland

2

Cyprus

2

Mexico

2

Slovenia

2

Argentina

2

Russia

2

Croatia

2

Taiwan, Province of China

1

Austria

1

Morocco

1

Chile

1

Luxembourg

1

Netherlands

1

Germany

1

Hungary

1

Belgium

2. List of Tracleer drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309126 ACTELION Dispersible bosentan tablet
May, 2026

(3 years from now)

US7959945 ACTELION Dispersible bosentan tablet
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 5, 2024

Drugs and Companies using BOSENTAN ingredient

Market Authorisation Date: 05 September, 2017

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of TRACLEER before it's patent expiration?
More Information on Dosage

TRACLEER family patents

4

United States

2

Korea, Republic of

2

Russia

2

European Union

1

Austria

1

Hong Kong

1

Brazil

1

Australia

1

Poland

1

Spain

1

Germany

1

Israel

1

Cyprus

1

Mexico

1

Japan

1

Slovenia

1

IB

1

South Africa

1

Portugal

1

China

1

Norway

1

New Zealand

1

Canada

1

Denmark

3. List of Uptravi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7205302 ACTELION Heterocyclic compound derivatives and medicines
Oct, 2026

(3 years from now)

US8791122 ACTELION Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
Aug, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173881 ACTELION Therapeutic compositions containing macitentan
Aug, 2029

(6 years from now)

US9284280 ACTELION Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
Jun, 2030

(7 years from now)

US10828298 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide
Dec, 2036

(13 years from now)

US10821108 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
Dec, 2036

(13 years from now)

Drugs and Companies using SELEXIPAG ingredient

Market Authorisation Date: 29 July, 2021

Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag; Method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a pharmaceutical composition comprising selexipag

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of UPTRAVI before it's patent expiration?
More Information on Dosage

UPTRAVI family patents

14

Japan

13

United States

7

European Union

5

Korea, Republic of

5

Brazil

5

Lithuania

5

Spain

5

Mexico

5

Hungary

5

Portugal

5

China

5

Denmark

4

Poland

4

Slovenia

4

Russia

4

Croatia

4

Canada

4

Taiwan, Province of China

3

Australia

3

Israel

3

Cyprus

3

Argentina

3

South Africa

3

Singapore

3

Philippines

3

Norway

2

Morocco

2

Hong Kong

2

Chile

2

Malaysia

2

Ukraine

2

IB

2

Colombia

2

New Zealand

1

Luxembourg

1

Netherlands

1

Germany

1

Belgium

1

Peru

1

Ecuador

4. List of Veletri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598227 ACTELION Epoprostenol formulation and method of making thereof
Feb, 2027

(3 years from now)

US8318802 ACTELION Epoprostenol formulation and method of making thereof
Mar, 2027

(4 years from now)

Drugs and Companies using EPOPROSTENOL SODIUM ingredient

Market Authorisation Date: 27 June, 2008

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of VELETRI before it's patent expiration?
More Information on Dosage

VELETRI family patents

10

United States

2

Canada

1

Slovenia

1

Hungary

1

Korea, Republic of

1

Brazil

1

Spain

1

Portugal

1

Poland

1

Russia

1

Cyprus

1

Denmark

1

China

1

Japan

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic